In this issue

Issue 101 • December 2020

News that two notable Covid-19 vaccine candidates had demonstrated 90% or greater efficacy in clinical trials has been music to the ears of many. The idea that the medical, financial and social impact of the pandemic may soon come to an end is a very welcome notion but, unfortunately, getting a vaccine from the lab, to market and then most importantly to the patients that need it – well, that’s a very complicated process.

With that in mind, we take a deep dive into the vaccine supply chain to find out what it will take to deliver a vaccine to patients around the world, as well as the hurdles that may stand in the way of a speedy distribution.

Before a vaccine even hits the market, it has to undergo Phase III trials. But what does that actually mean? We review the Phase III trial process to learn what goes into this ‘gold standard’ of testing.

Switching gears, we examine vaccine research in HIV to find out why a preventative vaccine has so far eluded researchers despite ground-breaking treatment innovation in the sector, find out what makes yeast a promising solution to supply chain vulnerabilities in plant-based drug ingredients, and investigate cancer treatment disparities across Europe.

All this and more in this latest issue of Pharma Technology Magazine.

Stay safe.

Eloise Mclennan, editor

Go to article: Home | The logistics of delivering a global vaccineGo to article: In this issueGo to article: ContentsGo to article: MimotopesGo to article: SHL MedicalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: SwiftpakGo to article: CommentGo to article: Long HCC pipeline marks change for a previously stagnant marketGo to article: Pfizer and BioNTech’s Covid-19 vaccine candidate shows 90% efficacyGo to article: Blockchain-enabled hospital can provide real-world dataGo to article: The increasing influence of industry sponsors along the pandemic timelineGo to article: Digitalisation in pharmaceutical manufacturingGo to article: VEGA AustraliaGo to article: KugelmeiersGo to article: Unither PharmaceuticalsGo to article: In DepthGo to article: Special delivery: the logistics of curing Covid-19 Go to article: Will there ever be an HIV vaccine?Go to article: Predicting Covid-19 vaccine approvals with OpylGo to article: Unequal access: understanding cancer treatment disparity in EuropeGo to article: ‘Trustpilot’ for medicines: can DrugsDiscovered help pharma be patient centric?Go to article: Q&A: investing in innovative biotechs with Novo VenturesGo to article: Gold standard: why are Phase III trials so critical?Go to article: Brewprint: using yeast to make plant-based drugsGo to article: Air FranceGo to article: Zenatek Company Insight Go to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue